HURA

TuHURA Biosciences, Inc. · NASDAQ · Healthcare · USD · 10-K for 2025, filed 2026-03-31

Figures on this page computed 2026-11-08 12:40 UTC

Last close

1.72USD

Market data, 2026-11-04

Except where said otherwise: 10-K for 2025, filed 2026-03-31

n/aP/E
We do not hold this figure for this company, so there is nothing to place.
Price / Earnings per Share (diluted)
Source
computed
Fiscal year
2025
Accession
0001193125-26-134950
Reported in
USD
- computed
- 10-K for 2025, filed 2026-03-31
The filing itself
n/aROIC
We do not hold this figure for this company, so there is nothing to place.
NOPAT / Invested Capital x 100, where NOPAT = Operating Income x (1 - Tax Rate) and Invested Capital = Equity + Total Debt - Cash
Source
computed
Fiscal year
2025
Accession
0001193125-26-134950
Reported in
USD
- 10-K for 2025, filed 2026-03-31
- 10-K for 2025, filed 2026-03-31
- 10-K for 2025, filed 2026-03-31
- 10-Q for 2025, filed 2026-08-14
- 10-K for 2025, filed 2026-03-31
- 10-Q for 2025, filed 2026-08-14
The filing itself
n/aNet margin
We do not hold this figure for this company, so there is nothing to place.
Net Income / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-134950
Reported in
USD
- 10-K for 2025, filed 2026-03-31
- 10-K for 2025, filed 2026-03-31
The filing itself
n/aFCF margin
We do not hold this figure for this company, so there is nothing to place.
Free Cash Flow / Revenue x 100
Source
computed
Fiscal year
2025
Accession
0001193125-26-134950
Reported in
USD
- 10-K for 2025, filed 2026-03-31
- 10-K for 2025, filed 2026-03-31
The filing itself
n/aDebt/equity
We do not hold this figure for this company, so there is nothing to place.
Total Debt / Shareholders' Equity
Source
computed
Fiscal year
2025
Accession
0001193125-26-134950
Reported in
USD
- 10-K for 2025, filed 2026-03-31
- 10-Q for 2025, filed 2026-08-14
The filing itself
n/aDividend yield
We do not hold this figure for this company, so there is nothing to place.
Source
computed
Taken on
2026-11-07
Reported in
USD
- computed

Safety is the furthest below its sector's middle: 0.13 against 0.72 on the market's range.

Margins: n/aWe do not hold this figure for this company, so there is nothing to place.
What it pays out: n/aWe do not hold this figure for this company, so there is nothing to place.

All from 100

lens 2 of 9

Profit

-339

2016-06-30 to 2025-12-31100 at the start-339

Profit: 100.00 on 2016-06-30 to -339.00 on 2025-12-31, down 439%.

Shares in issue

7,660,660

2016-06-30 to 2025-12-31100 at the start7,660,660

Shares in issue: 100.00 on 2016-06-30 to 7660660.23 on 2025-12-31, up 7660560%.

Sales, where the first year is 100: n/aNot enough filed years carry this line for it to be drawn. No line is drawn flat in its place.

Profit is at -339, Shares in issue is at 7660660, against 100 in 2016.

Every figure in this lens

Except where said otherwise: 10-K for 2025, filed 2026-03-31

Sales, where the first year is 100n/a
Not held.
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-134950
Reported in
USD
The filing itself
Profit, where the first year is 100-339
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-134950
Reported in
USD
The filing itself
Shares in issue, where the first year is 1007,660,660
Source
filed
Statement
income
Fiscal year
2025
Accession
0001193125-26-134950
Reported in
USD
The filing itself